Free Trial

Citigroup's Rating of Larimar Therapeutics on 6/30/2026

On June 30, 2026, Citigroup updated its outlook on Larimar Therapeutics (NASDAQ:LRMR) with the action "Reiterated Rating", keeping a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Citigroup Inc.

DateCompanyAction
11/11/2026
Omega Healthcare Investors, Inc. stock logo
OHI
Omega Healthcare Investors
Reiterated Rating
11/11/2026
Energy Vault Holdings, Inc. stock logo
NRGV
Energy Vault
Boost Price Target
11/11/2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
Boost Price Target
11/11/2026
EPAM Systems, Inc. stock logo
EPAM
EPAM Systems
Boost Price Target
11/11/2026
GMR Solutions Inc. stock logo
GMRS
GMR Solutions
Lower Price Target
11/11/2026
Fiserv, Inc. stock logo
FISV
Fiserv
Boost Price Target
More Ratings From Citigroup Inc.